Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DUCCIO BALDARI

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1992786503
CMS profile
316630
Location
WELLINGTON, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$31,931.78

232 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

Page 5 of 5; records 201–232 of 232 matching records. This page contains 32 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DUCCIO BALDARI

NPI 1992786503 · CMS profile ID 316630

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

WELLINGTON, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 5; records 201–232 of 232 matching records. This page contains 32 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1992786503?year=2022&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DUCCIO BALDARI, NPI 1992786503, CMS profile ID 316630. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–232 of 232 matching records. This page contains 32 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1992786503?year=2022&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). DUCCIO BALDARI, NPI 1992786503, CMS profile ID 316630. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–232 of 232 matching records. This page contains 32 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1992786503?year=2022&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
DUCCIO BALDARI, NPI 1992786503, CMS profile ID 316630, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 5; records 201–232 of 232 matching records. This page contains 32 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1992786503?year=2022&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

232 matching records · $31,931.78 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 232 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–232 of 232.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $6.8302/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939170757 CMS
Janssen Pharmaceuticals, Inc $5.4802/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886021979 CMS
E.R. Squibb & Sons, L.L.C. $2.8702/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932937297 CMS
Novartis Pharmaceuticals Corporation $4.7402/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893516581 CMS
Impulse Dynamics (USA) Inc. $40.9302/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947545807 CMS
Janssen Pharmaceuticals, Inc $11.3702/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886021667 CMS
E.R. Squibb & Sons, L.L.C. $5.0002/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932937295 CMS
Janssen Pharmaceuticals, Inc $8.8802/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886021931 CMS
Bard Peripheral Vascular, Inc. $50.7802/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 936009031 CMS
Amarin Pharma Inc. $24.1701/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 913912245 CMS
Janssen Pharmaceuticals, Inc $7.8501/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886021923 CMS
Bayer HealthCare Pharmaceuticals Inc. $17.5101/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930156893 CMS
Esperion Therapeutics, Inc. $14.3801/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947242567 CMS
Janssen Pharmaceuticals, Inc $5.7901/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886021917 CMS
Janssen Pharmaceuticals, Inc $8.6901/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886021631 CMS
Novartis Pharmaceuticals Corporation $19.2001/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893516577 CMS
Amgen Inc. $9.3001/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939170751 CMS
Janssen Pharmaceuticals, Inc $11.2001/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886021637 CMS
Bard Peripheral Vascular, Inc. $29.7501/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 936009301 CMS
Janssen Pharmaceuticals, Inc $8.5601/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886021809 CMS
Chiesi USA, Inc. $13.8701/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 960787713 CMS
Janssen Pharmaceuticals, Inc $14.9301/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886021803 CMS
Janssen Pharmaceuticals, Inc $1,000.0001/11/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886021503 CMS
Amgen Inc. $11.0801/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939170749 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $20.5001/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887793791 CMS
Bayer HealthCare Pharmaceuticals Inc. $16.4401/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930273527 CMS
E.R. Squibb & Sons, L.L.C. $15.8301/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932937441 CMS
E.R. Squibb & Sons, L.L.C. $3.5001/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932937443 CMS
Merck Sharp & Dohme LLC $16.4001/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944065145 CMS
Janssen Pharmaceuticals, Inc $12.6701/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886021741 CMS
Novartis Pharmaceuticals Corporation $17.1701/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893516573 CMS
Novartis Pharmaceuticals Corporation $4.1201/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893516575 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $34,438.08 201
PY2020 $15,531.88 116
PY2021 $19,625.86 271
PY2022 $31,931.78 232
PY2023 $23,428.10 222
PY2024 $28,011.04 226
PY2025 $3,682.34 169

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $497,099.10 18
PY2024 Principal investigator $496,338.63 9
PY2023 Principal investigator $440,690.16 25
PY2022 Principal investigator $446,130.18 42
PY2021 Principal investigator $271,689.40 32
PY2020 Principal investigator $390,102.20 25
PY2019 Principal investigator $804,830.36 49

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

18 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Eli Lilly and Company $2,447.00 12/16/2025 Non-covered Recipient Entity
CARDIOLOGY PARTNERS CLINICAL
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187880641
Principal investigator 1 Alnylam Pharmaceuticals Inc. $6,000.00 12/12/2025 Non-covered Recipient Entity
Cardiology Partners
A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease No dispute reported 06/30/2026 1215508801
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,598.00 12/12/2025 Non-covered Recipient Entity
Cardiology Partners
A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease No dispute reported 06/30/2026 1215508805
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Cardiology Partners Palm Beach Gardens Office
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220717209
Principal investigator 1 Boehringer Ingelheim International GmbH $23.75 12/01/2025 Non-covered Recipient Entity
Cardiology Partners Palm Beach Gardens Office
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220717211
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 12/01/2025 Non-covered Recipient Entity
Cardiology Partners Palm Beach Gardens Office
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220717213
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 12/01/2025 Non-covered Recipient Entity
Cardiology Partners Palm Beach Gardens Office
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220717215
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,109.24 11/12/2025 Non-covered Recipient Entity
CARDIOLOGY PARTNERS CLINICAL RESEARCH INSTITUTE
A multi-center, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study to evaluate efficacy, safety, and tolerability of DII235 in adults with elevated lipoprotein(a) No dispute reported 06/30/2026 1190314043
Principal investigator 1 Amgen Inc. $3,897.36 08/19/2025 Non-covered Recipient Entity
CARDIOLOGY PARTNERS CLINICAL RESEARCH INSTITUTE
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF) No dispute reported 06/30/2026 1246639977
Principal investigator 1 Amgen Inc. $50,625.00 06/08/2025 Non-covered Recipient Entity
CARDIOLOGY PARTNERS CLINICAL RESEARCH INSTITUTE
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity No dispute reported 06/30/2026 1246639979
Principal investigator 1 Novartis Pharmaceuticals Corporation $39,991.62 05/20/2025 Non-covered Recipient Entity
CARDIOLOGY PARTNERS CLINICAL RESEARCH INSTITUTE
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD No dispute reported 06/30/2026 1190313071
Principal investigator 1 Novartis Pharmaceuticals Corporation $97,962.88 03/31/2025 Non-covered Recipient Entity
CARDIOLOGY PARTNERS CLINICAL RESEARCH INSTITUTE
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190313629
Principal investigator 1 Novartis Pharmaceuticals Corporation $52,641.17 03/25/2025 Non-covered Recipient Entity
CARDIOLOGY PARTNERS CLINICAL RESEARCH INSTITUTE
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190313065
Principal investigator 1 AstraZeneca UK Limited $8,745.00 03/17/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase III Randomised Doubleblind Study to Evaluate the Effect of Balcinrenone Dapagliflozin Compared with Dapagliflozin on the Risk of Heart Failure Events and Cardiovascular Death in Patients with Heart Failure and Impaired Kidney Function No dispute reported 06/30/2026 1185538402
Principal investigator 1 Novartis Pharmaceuticals Corporation $20,321.80 02/11/2025 Non-covered Recipient Entity
CARDIOLOGY PARTNERS, LLC
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190301361
Principal investigator 1 Novartis Pharmaceuticals Corporation $131,393.03 02/04/2025 Non-covered Recipient Entity
CARDIOLOGY PARTNERS, LLC
A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi No dispute reported 06/30/2026 1190301367
Principal investigator 1 Novartis Pharmaceuticals Corporation $41,735.00 01/30/2025 Non-covered Recipient Entity
CARDIOLOGY PARTNERS, LLC
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190301357
Principal investigator 1 Novartis Pharmaceuticals Corporation $37,449.81 01/20/2025 Non-covered Recipient Entity
CARDIOLOGY PARTNERS CLINICAL RESEARCH INSTITUTE
A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi No dispute reported 06/30/2026 1190313069